The Role of Tregs in Glioma-Mediated Immunosuppression: Potential Target for Intervention

Neurosurgery Clinics of North America

Volumn 21, Issue 1, 2010, Pages 125-137

  Humphries, William ^a   Wei, Jun ^a   Sampson, John H ^b   Heimberger, Amy B ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Central nervous system; Glioblastoma multiforme; Immunotherapy; Prognosis; Regulatory T cells; Vaccine

Indexed keywords

AMINOTRANSFERASE; ANTINEOPLASTIC AGENT; BASILIXIMAB; CYCLOPHOSPHAMIDE; CYTOKINE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4 ANTIBODY; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4 BLOCKING AGENT; DENILEUKIN DIFTITOX; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IMMUNOTOXIN LMB2; INTERLEUKIN 2; MELANOMA VACCINE; PEPTIDE VACCINE; RICIN A; STAT3 PROTEIN BLOCKING AGENT; TEMOZOLOMIDE; UNCLASSIFIED DRUG; WP 1066;

AMINOTRANSFERASE BLOOD LEVEL; ANTIGEN ANTIBODY REACTION; ANTINEOPLASTIC ACTIVITY; AUTOIMMUNE DISEASE; CANCER COMBINATION CHEMOTHERAPY; CANCER GRADING; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CD4+ CD25+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL SURVIVAL; CELLULAR IMMUNITY; CLINICAL TRIAL; CYTOKINE PRODUCTION; CYTOLOGY; DERMATITIS; DRUG FEVER; DRUG MECHANISM; DRUG MEGADOSE; DRUG POTENTIATION; DRUG TARGETING; DYSPNEA; EDEMA; ENTEROCOLITIS; GLIOBLASTOMA; HAIRY CELL LEUKEMIA; HEPATITIS; HODGKIN DISEASE; HUMAN; HUMORAL IMMUNITY; HYPOPHYSITIS; IMMUNOLOGICAL TOLERANCE; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; LOW DRUG DOSE; LYMPHOCYTE PROLIFERATION; MELANOMA; MONOTHERAPY; MYALGIA; NONHUMAN; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; REGULATORY T LYMPHOCYTE; REVIEW; SIDE EFFECT; SINGLE DRUG DOSE; UVEITIS; WEAKNESS;

ANIMALS; BRAIN NEOPLASMS; CENTRAL NERVOUS SYSTEM; GLIOMA; HUMANS; IMMUNE TOLERANCE; IMMUNOTHERAPY; PROGNOSIS; T-LYMPHOCYTES, REGULATORY;

EID: 70450176686     PISSN: 10423680     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nec.2009.08.012     Document Type: Review

References (124)

1. Yi-qun Z., Lorre K., de Boer M., et al. B7-blocking agents, alone or in combination with cyclosporin A, induce antigen-specific anergy of human memory T cells. J Immunol 158 (1997) 4734-4740
2. Lim H.W., Hillsamer P., Banham A.H., et al. Cutting edge: direct suppression of B cells by CD4+ CD25+ regulatory T cells. J Immunol 175 (2005) 4180-4183
3. Zhao D.M., Thornton A.M., DiPaolo R.J., et al. Activated CD4+CD25+ T cells selectively kill B lymphocytes. Blood 107 (2006) 3925-3932
4. Fallarino F., Grohmann U., Hwang K.W., et al. Modulation of tryptophan catabolism by regulatory T cells. Nat Immunol 4 (2003) 1206-1212
5. Misra N., Bayry J., Lacroix-Desmazes S., et al. Cutting edge: human CD4+CD25+ T cells restrain the maturation and antigen-presenting function of dendritic cells. J Immunol 172 (2004) 4676-4680
6. Taams L.S., van Amelsfort J.M., Tiemessen M.M., et al. Modulation of monocyte/macrophage function by human CD4+CD25+ regulatory T cells. Hum Immunol 66 (2005) 222-230
7. Azuma T., Takahashi T., Kunisato A., et al. Human CD4+ CD25+ regulatory T cells suppress NKT cell functions. Cancer Res 63 (2003) 4516-4520
8. Ralainirina N., Poli A., Michel T., et al. Control of NK cell functions by CD4+CD25+ regulatory T cells. J Leukoc Biol 81 (2007) 144-153
9. Smyth M.J., Teng M.W., Swann J., et al. CD4+CD25+ T regulatory cells suppress NK cell-mediated immunotherapy of cancer. J Immunol 176 (2006) 1582-1587
10. Dieckmann D., Plottner H., Berchtold S., et al. Ex vivo isolation and characterization of CD4(+)CD25(+) T cells with regulatory properties from human blood. J Exp Med 193 (2001) 1303-1310
11. Fontenot J.D., Gavin M.A., and Rudensky A.Y. Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. Nat Immunol 4 (2003) 330-336
12. Jonuleit H., Schmitt E., Stassen M., et al. Identification and functional characterization of human CD4(+)CD25(+) T cells with regulatory properties isolated from peripheral blood. J Exp Med 193 (2001) 1285-1294
13. Khattri R., Cox T., Yasayko S.A., et al. An essential role for Scurfin in CD4+CD25+ T regulatory cells. Nat Immunol 4 (2003) 337-342
14. Thornton A.M., and Shevach E.M. CD4+CD25+ immunoregulatory T cells suppress polyclonal T cell activation in vitro by inhibiting interleukin 2 production. J Exp Med 188 (1998) 287-296
15. Sakaguchi S. Naturally arising CD4+ regulatory T cells for immunologic self-tolerance and negative control of immune responses. Annu Rev Immunol 22 (2004) 531-562
16. Asano M., Toda M., Sakaguchi N., et al. Autoimmune disease as a consequence of developmental abnormality of a T cell subpopulation. J Exp Med 184 (1996) 387-396
17. Bagavant H., Thompson C., Ohno K., et al. Differential effect of neonatal thymectomy on systemic and organ-specific autoimmune disease. Int Immunol 14 (2002) 1397-1406
18. Miyara M., and Sakaguchi S. Natural regulatory T cells: mechanisms of suppression. Trends Mol Med 13 (2007) 108-116
19. Sakaguchi S., Sakaguchi N., Asano M., et al. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol 155 (1995) 1151-1164
20. Salomon B., Lenschow D.J., Rhee L., et al. B7/CD28 costimulation is essential for the homeostasis of the CD4+CD25+ immunoregulatory T cells that control autoimmune diabetes. Immunity 12 (2000) 431-440
21. Seddon B., and Mason D. Regulatory T cells in the control of autoimmunity: the essential role of transforming growth factor beta and interleukin 4 in the prevention of autoimmune thyroiditis in rats by peripheral CD4(+)CD45RC- cells and CD4(+)CD8(-) thymocytes. J Exp Med 189 (1999) 279-288
22. Stephens L.A., and Mason D. CD25 is a marker for CD4+ thymocytes that prevent autoimmune diabetes in rats, but peripheral T cells with this function are found in both CD25+ and CD25- subpopulations. J Immunol 165 (2000) 3105-3110
23. Taguchi O., Kontani K., Ikeda H., et al. Tissue-specific suppressor T cells involved in self-tolerance are activated extrathymically by self-antigens. Immunology 82 (1994) 365-369
24. Taguchi O., and Nishizuka Y. Self tolerance and localized autoimmunity. Mouse models of autoimmune disease that suggest tissue-specific suppressor T cells are involved in self tolerance. J Exp Med 165 (1987) 146-156
25. Curiel T.J., Coukos G., Zou L., et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 10 (2004) 942-949
26. Somasundaram R., Jacob L., Swoboda R., et al. Inhibition of cytolytic T lymphocyte proliferation by autologous CD4+/CD25+ regulatory T cells in a colorectal carcinoma patient is mediated by transforming growth factor-beta. Cancer Res 62 (2002) 5267-5272
27. Fecci P.E., Mitchell D.A., Whitesides J.F., et al. Increased regulatory T-cell fraction amidst a diminished CD4 compartment explains cellular immune defects in patients with malignant glioma. Cancer Res 66 (2006) 3294-3302
28. Fecci P.E., Ochiai H., Mitchell D.A., et al. Systemic CTLA-4 blockade ameliorates glioma-induced changes to the CD4+ T cell compartment without affecting regulatory T-cell function. Clin Cancer Res 13 (2007) 2158-2167
29. Fecci P.E., Sweeney A.E., Grossi P.M., et al. Systemic anti-CD25 monoclonal antibody administration safely enhances immunity in murine glioma without eliminating regulatory T cells. Clin Cancer Res 12 (2006) 4294-4305
30. Gershon R.K., and Kondo K. Infectious immunological tolerance. Immunology 21 (1971) 903-914
31. Knutson K.L., Disis M.L., and Salazar L.G. CD4 regulatory T cells in human cancer pathogenesis. Cancer Immunol Immunother 56 (2007) 271-285
32. Bluestone J.A., and Abbas A.K. Natural versus adaptive regulatory T cells. Nat Rev Immunol 3 (2003) 253-257
33. Mitchell D.A., Fecci P.E., and Sampson J.H. Immunotherapy of malignant brain tumors. Immunol Rev 222 (2008) 70-100
34. Jonuleit H., and Schmitt E. The regulatory T cell family: distinct subsets and their interrelations. J Immunol 171 (2003) 6323-6327
35. Takahashi T., Tagami T., Yamazaki S., et al. Immunologic self-tolerance maintained by CD25(+)CD4(+) regulatory T cells constitutively expressing cytotoxic T lymphocyte-associated antigen 4. J Exp Med 192 (2000) 303-310
36. Brunet J.F., Denizot F., Luciani M.F., et al. A new member of the immunoglobulin superfamily-CTLA-4. Nature 328 (1987) 267-270
37. Walunas T.L., Lenschow D.J., Bakker C.Y., et al. CTLA-4 can function as a negative regulator of T cell activation. Immunity 1 (1994) 405-413
38. Hori S., and Sakaguchi S. Foxp3: a critical regulator of the development and function of regulatory T cells. Microbes Infect 6 (2004) 745-751
39. Kretschmer K., Apostolou I., Hawiger D., et al. Inducing and expanding regulatory T cell populations by foreign antigen. Nat Immunol 6 (2005) 1219-1227
40. Chen W., Jin W., Hardegen N., et al. Conversion of peripheral CD4+CD25- naive T cells to CD4+CD25+ regulatory T cells by TGF-beta induction of transcription factor Foxp3. J Exp Med 198 (2003) 1875-1886
41. Scotta C., Soligo M., Camperio C., et al. FOXP3 induced by CD28/B7 interaction regulates CD25 and anergic phenotype in human CD4+CD25- T lymphocytes. J Immunol 181 (2008) 1025-1033
42. Groux H. Type 1 T-regulatory cells: their role in the control of immune responses. Transplantation 75 (2003) 8S-12S
43. Chen Y., Kuchroo V.K., Inobe J., et al. Regulatory T cell clones induced by oral tolerance: suppression of autoimmune encephalomyelitis. Science 265 (1994) 1237-1240
44. Weiner H.L. Induction and mechanism of action of transforming growth factor-beta-secreting Th3 regulatory cells. Immunol Rev 182 (2001) 207-214
45. Liyanage U.K., Moore T.T., Joo H.G., et al. Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma. J Immunol 169 (2002) 2756-2761
46. Wolf A.M., Wolf D., Steurer M., et al. Increase of regulatory T cells in the peripheral blood of cancer patients. Clin Cancer Res 9 (2003) 606-612
47. Dix A.R., Brooks W.H., Roszman T.L., et al. Immune defects observed in patients with primary malignant brain tumors. J Neuroimmunol 100 (1999) 216-232
48. Morford L.A., Elliott L.H., Carlson S.L., et al. T cell receptor-mediated signaling is defective in T cells obtained from patients with primary intracranial tumors. J Immunol 159 (1997) 4415-4425
49. Roszman T.L., and Brooks W.H. Immunobiology of primary intracranial tumours. III. Demonstration of a qualitative lymphocyte abnormality in patients with primary brain tumours. Clin Exp Immunol 39 (1980) 395-402
50. Hussain S.F., Yang D., Suki D., et al. The role of human glioma-infiltrating microglia/macrophages in mediating antitumor immune responses. Neuro Oncol 8 (2006) 261-279
51. El Andaloussi A., and Lesniak M.S. An increase in CD4+CD25+FOXP3+ regulatory T cells in tumor-infiltrating lymphocytes of human glioblastoma multiforme. Neuro Oncol 8 (2006) 234-243
52. Jordan J.T., Sun W.H., Hussain S.F., et al. Preferential migration of regulatory T cells mediated by glioma-secreted chemokines can be blocked with chemotherapy. Cancer Immunol Immunother 57 (2008) 123-131
53. Grauer O.M., Nierkens S., Bennink E., et al. CD4+FoxP3+ regulatory T cells gradually accumulate in gliomas during tumor growth and efficiently suppress antiglioma immune responses in vivo. Int J Cancer 121 (2007) 95-105
54. Hickey W.F., Hsu B.L., and Kimura H. T-lymphocyte entry into the central nervous system. J Neurosci Res 28 (1991) 254-260
55. von Hanwehr R.I., Hofman F.M., Taylor C.R., et al. Mononuclear lymphoid populations infiltrating the microenvironment of primary CNS tumors. Characterization of cell subsets with monoclonal antibodies. J Neurosurg 60 (1984) 1138-1147
56. Brooks W.H., Markesbery W.R., Gupta G.D., et al. Relationship of lymphocyte invasion and survival of brain tumor patients. Ann Neurol 4 (1978) 219-224
57. Strik H.M., Stoll M., and Meyermann R. Immune cell infiltration of intrinsic and metastatic intracranial tumours. Anticancer Res 24 (2004) 37-42
58. Safdari H., Hochberg F.H., and Richardson Jr. E.P. Prognostic value of round cell (lymphocyte) infiltration in malignant gliomas. Surg Neurol 23 (1985) 221-226
59. Heimberger A.B., Reina-Ortiz C., Yang D.S., et al. Incidence and prognostic impact of FoxP3+ regulatory T cells in human gliomas. Clin Cancer Res 14 (2008) 5166-5172
60. Attia P., Maker A.V., Haworth L.R., et al. Inability of a fusion protein of IL-2 and diphtheria toxin (Denileukin Diftitox, DAB389IL-2, ONTAK) to eliminate regulatory T lymphocytes in patients with melanoma. J Immunother 28 (2005) 582-592
61. Foss F. Clinical Experience With Denileukin Diftitox (ONTAK). Semin Oncol 33 (2006) 11-16
62. North R.J. Cyclophosphamide-facilitated adoptive immunotherapy of an established tumor depends on elimination of tumor-induced suppressor T cells. J Exp Med 155 (1982) 1063-1074
63. Kong L.-K., Wei J., Sharma A.K., et al. A novel phosphorylated STAT3 inhibitor enhances T cell cytotoxicity against melanoma through inhibition of regulatory T cells. Cancer Immunol Immunother 58 (2008) 1023-1032
64. Kong L.Y., Abou-Ghazal M.K., Wei J., et al. A novel inhibitor of STAT3 activation is efficacious against established central nervous system melanoma and inhibits regulatory T cells. Clin Cancer Res 14 (2008) 5759-5768
65. Jordan J.T., Sun W.H., Hussain S.F., et al. Preferential migration of regulatory T cells mediated by glioma-secreted chemokines can be blocked with chemotherapy. Cancer Immunol Immunother 57 (2008) 123-131
66. Cheever M.A., Greenberg P.D., and Fefer A. Specificity of adoptive chemoimmunotherapy of established syngeneic tumors. J Immunol 125 (1980) 711-714
67. Dudley M.E., Wunderlich J.R., Robbins P.F., et al. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 298 (2002) 850-854
68. Dudley M.E., Wunderlich J.R., Yang J.C., et al. Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J Clin Oncol 23 (2005) 2346-2357
69. Kedl R.M., Rees W.A., Hildeman D.A., et al. T cells compete for access to antigen-bearing antigen-presenting cells. J Exp Med 192 (2000) 1105-1113
70. Gattinoni L., Finkelstein S.E., Klebanoff C.A., et al. Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells. J Exp Med 202 (2005) 907-912
71. Klebanoff C.A., Khong H.T., Antony P.A., et al. Sinks, supressors and antigen presenters: how lymphodepletion enhances T cell-mediated tumor immunotherapy [Erratum appears in Trends Immunol 2005;26:298]. Trends Immunol 26 (2005) 111-117
72. Taieb J., Chaput N., Schartz N., et al. Chemoimmunotherapy of tumors: cyclophosphamide synergizes with exosome based vaccines. J Immunol 176 (2006) 2722-2729
73. Ercolini A.M., Ladle B.H., Manning E.A., et al. Recruitment of latent pools of high-avidity CD8+ T cells to the antitumor immune response. J Exp Med 201 (2005) 1591-1602
74. Tsung K., Meko J.B., Tsung Y.L., et al. Immune response against large tumors eradicated by treatment with cyclophosphamide and IL-12. J Immunol 160 (1998) 1369-1377
75. Hengst J.C.D., Mokyr M.B., and Dray S. Importance of timing in cyclophosphamide therapy in MOPC-315 tumor-bearing mice. Cancer Res 40 (1980) 2135-2141
76. Hengst J.C.D., Mokyr M.B., and Dray S. Cooperation between cyclophosphamide tumoricidal activity and host antitumor immunity in the cure of mice bearing large MOPC-315 tumors. Cancer Res 41 (1981) 2163-2167
77. Holtl L., Ramoner R., Zelle-Rieser C., et al. Allogeneic dendritic cell vaccination against metastatic renal cell carcinoma with or without cyclophosphamide. Cancer Immunol Immunother 54 (2005) 663-670
78. MacLean G.D., Miles D.W., Rubens R.D., et al. Enhancing the effect of THERATOPE STn-KLH cancer vaccine in patients with metastatic breast cancer by pretreatment with low-dose intravenous cyclophosphamide. J Immunother Emphasis Tumor Immunol 19 (1996) 309-316
79. Berd D., Maguire H.C., McCue P., et al. Treatment of metastatic melanoma with an autologous tumor-cell vaccine: clinical and immunological results in 64 patients. J Clin Oncol 8 (1990) 1858-1867
80. Plautz G.E., Miller D.W., Barnett G.H., et al. T cell adoptive immunotherapy of newly diagnosed gliomas. Clin Cancer Res 6 (2000) 2209-2218
81. Hermans I.F., Chong T.W., Palmowski M.J., et al. Synergistic effect of metronomic dosing of cyclophosphamide combined with specific antitumor immunotherapy in a murine melanoma model. Cancer Res 63 (2003) 8408-8413
82. Ghiringhelli F., Menard C., Puig P.E., et al. Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients. Cancer Immunol Immunother 56 (2007) 641-648
83. Kanzawa T., Germano I.M., Komata T., et al. Role of autophagy in temozolomide-induced cytotoxicity for malignant glioma cells. Cell Death Differ 11 (2004) 448-457
84. Su Y.B., Sohn S., Krown S.E., et al. Selective CD4+ lymphopenia in melanoma patients treated with temozolomide: a toxicity with therapeutic implications. J Clin Oncol 22 (2004) 610-616
85. Sampson J.H., Archer G.E., Bigner D.D., et al. Effect of EGFRvIII-targeted vaccine (CDX-110) induces immune responses and prolongs TTP when given with simultaneous standard and continuous temozolomide in patients with GBM. J Clin Oncol 26 Suppl (2008) 92s
86. El Andaloussi A., Han Y., and Lesniak M.S. Prolongation of survival following depletion of CD4+CD25+ regulatory T cells in mice with experimental brain tumors. J Neurosurg 105 (2006) 430-437
87. Read S., Malmstrom V., and Powrie F. Cytotoxic T lymphocyte-associated antigen 4 plays an essential role in the function of CD25(+)CD4(+) regulatory cells that control intestinal inflammation. J Exp Med 192 (2000) 295-302
88. Eggena M.P., Walker L.S., Nagabhushanam V., et al. Cooperative roles of CTLA-4 and regulatory T cells in tolerance to an islet cell antigen. J Exp Med 199 (2004) 1725-1730
89. Sutmuller R.P., van Duivenvoorde L.M., van Elsas A., et al. Synergism of cytotoxic T lymphocyte-associated antigen 4 blockade and depletion of CD25(+) regulatory T cells in antitumor therapy reveals alternative pathways for suppression of autoreactive cytotoxic T lymphocyte responses. J Exp Med 194 (2001) 823-832
90. Sampson J.H., Ashley D.M., Archer G.E., et al. Characterization of a spontaneous murine astrocytoma and abrogation of its tumorigenicity by cytokine secretion. Neurosurgery 41 (1997) 1365-1372 [discussion: 72-3]
91. Oukka M. Interplay between pathogenic Th17 and regulatory T cells. Ann Rheum Dis 66 Suppl 3 (2007) iii87-iii90
92. Leach D.R., Krummel M.F., and Allison J.P. Enhancement of antitumor immunity by CTLA-4 blockade. Science 271 (1996) 1734-1736
93. Shrikant P., Khoruts A., and Mescher M.F. CTLA-4 blockade reverses CD8+ T cell tolerance to tumor by a CD4+ T cell- and IL-2-dependent mechanism. Immunity 11 (1999) 483-493
94. Sotomayor E.M., Borrello I., Tubb E., et al. In vivo blockade of CTLA-4 enhances the priming of responsive T cells but fails to prevent the induction of tumor antigen-specific tolerance. Proc Natl Acad Sci U S A 96 (1999) 11476-11481
95. Yang Y.F., Zou J.P., Mu J., et al. Enhanced induction of antitumor T-cell responses by cytotoxic T lymphocyte-associated molecule-4 blockade: the effect is manifested only at the restricted tumor-bearing stages. Cancer Res 57 (1997) 4036-4041
96. Hodi F.S., Mihm M.C., Soiffer R.J., et al. Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients. Proc Natl Acad Sci U S A 100 (2003) 4712-4717
97. Phan G.Q., Yang J.C., Sherry R.M., et al. Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc Natl Acad Sci U S A 100 (2003) 8372-8377
98. Small E.J., Tchekmedyian N.S., Rini B.I., et al. A pilot trial of CTLA-4 blockade with human anti-CTLA-4 in patients with hormone-refractory prostate cancer. Clin Cancer Res 13 (2007) 1810-1815
99. Theoret M.R., Arlen P.M., Pazdur M., et al. Phase I trial of an enhanced prostate-specific antigen-based vaccine and anti-CTLA-4 antibody in patients with metastatic androgen-independent prostate cancer. Clin Genitourin Cancer 5 (2007) 347-350
100. Blansfield J.A., Beck K.E., Tran K., et al. Cytotoxic T-lymphocyte-associated antigen-4 blockage can induce autoimmune hypophysitis in patients with metastatic melanoma and renal cancer. J Immunother 28 (2005) 593-598
101. Reuben JM, Lee BN, Shen DY, et al. Therapy with human monoclonal anti-CTLA-4 antibody, CP-675,206, reduces regulatory T cells and IL-10 production in patients with advanced malignant melanoma [abstract 7505]. In: 2005 American Society of Clinical Oncology Annual Meeting. Orlando (FL), May 13-17, 2005.
102. Attia P., Phan G.Q., Maker A.V., et al. Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4. J Clin Oncol 23 (2005) 6043-6053
103. Yuan J., Gnjatic S., Li H., et al. CTLA-4 blockade enhances polyfunctional NY-ESO-1 specific T cell responses in metastatic melanoma patients with clinical benefit. Proc Natl Acad Sci U S A 105 (2008) 20410-20415
104. Maker A.V., Phan G.Q., Attia P., et al. Tumor regression and autoimmunity in patients treated with cytotoxic T lymphocyte-associated antigen 4 blockade and interleukin 2: a phase I/II study. Ann Surg Oncol 12 (2005) 1005-1016
105. Hodi F.S., Butler M., Oble D.A., et al. Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients. Proc Natl Acad Sci U S A 105 (2008) 3005-3010
106. Heimberger A.B., Hussain S.F., Aldape K., et al. Tumor-specific peptide vaccination in newly-diagnosed patients with GBM. J Clin Oncol 24 (2006) Part 1
107. Sampson J.H., Aldape K.D., Gilbert M.R., et al. Temozolomide as a vaccine adjuvant in GBM. J Clin Oncol 25 Suppl (2007) 18S
108. Engert A., Diehl V., Schnell R., et al. A phase-I study of an anti-CD25 ricin A-chain immunotoxin (RFT5-SMPT-dgA) in patients with refractory Hodgkin's lymphoma. Blood 89 (1997) 403-410
109. Schnell R., Vitetta E., Schindler J., et al. Clinical trials with an anti-CD25 ricin A-chain experimental and immunotoxin (RFT5-SMPT-dgA) in Hodgkin's lymphoma. Leuk Lymphoma 30 (1998) 525-537
110. Kreitman R.J., Wilson W.H., Robbins D., et al. Responses in refractory hairy cell leukemia to a recombinant immunotoxin. Blood 94 (1999) 3340-3348
111. Schnell R., Vitetta E., Schindler J., et al. Treatment of refractory Hodgkin's lymphoma patients with an anti-CD25 ricin A-chain immunotoxin. Leukemia 14 (2000) 129-135
112. Kreitman R.J., Wilson W.H., White J.D., et al. Phase I trial of recombinant immunotoxin anti-Tac(Fv)-PE38 (LMB-2) in patients with hematologic malignancies. J Clin Oncol 18 (2000) 1622-1636
113. Dannull J., Su Z., Rizzieri D., et al. Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells. J Clin Invest 115 (2005) 3623-3633
114. Dang N.H., Hagemeister F.B., Pro B., et al. Phase II study of denileukin diftitox for relapsed/refractory B-Cell non-Hodgkin's lymphoma. J Clin Oncol 22 (2004) 4095-4102
115. Miescher S., Whiteside T.L., de Tribolet N., et al. In situ characterization, clonogenic potential, and antitumor cytolytic activity of T lymphocytes infiltrating human brain cancers. J Neurosurg 68 (1988) 438-448
116. Fontana A., Hengartner H., de Tribolet N., et al. Glioblastoma cells release interleukin 1 and factors inhibiting interleukin 2-mediated effects. J Immunol 132 (1984) 1837-1844
117. Roszman T.L., Brooks W.H., and Elliott L.H. Inhibition of lymphocyte responsiveness by a glial tumor cell- derived suppressive factor. J Neurosurg 67 (1987) 874-879
118. Meng Y., Carpentier A.F., Chen L., et al. Successful combination of local CpG-ODN and radiotherapy in malignant glioma. Int J Cancer 116 (2005) 992-997
119. Peng G., Guo Z., Kiniwa Y., et al. Toll-like receptor 8-mediated reversal of CD4+ regulatory T cell function. Science 309 (2005) 1380-1384
120. Grauer O.M., Molling J.W., Bennink E., et al. TLR ligands in the local treatment of established intracerebral murine gliomas. J Immunol 181 (2008) 6720-6729
121. Hoyne G.F., Le Roux I., Corsin-Jimenez M., et al. Serrate1-induced notch signalling regulates the decision between immunity and tolerance made by peripheral CD4(+) T cells. Int Immunol 12 (2000) 177-185
122. Kinjyo I., Inoue H., Hamano S., et al. Loss of SOCS3 in T helper cells resulted in reduced immune responses and hyperproduction of interleukin 10 and transforming growth factor-beta 1. J Exp Med 203 (2006) 1021-1031
123. Zorn E., Nelson E.A., Mohseni M., et al. IL-2 regulates FOXP3 expression in human CD4+CD25+ regulatory T cells through a STAT-dependent mechanism and induces the expansion of these cells in vivo. Blood 108 (2006) 1571-1579
124. Kortylewski M., Kujawski M., Wang T., et al. Inhibiting Stat3 signaling in the hematopoietic system elicits multicomponent antitumor immunity. Nat Med 11 (2005) 1314-1321